Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia (NASDAQ:LQDA) reported strong first quarter 2026 results driven by YUTREPIA inhalation powder. Product sales, net, reached $129.9 million, supporting net income of $52.9 million and adjusted EBITDA of $71.2 million. Cash and cash equivalents rose to $222.8 million.
Since YUTREPIA’s June 2025 launch, more than 4,500 unique prescriptions were received and about 3,750 patients started treatment, with conversion at or above 85%. Liquidia is also screening PH-ILD patients in Phase 4 Tyvaso/Tyvaso DPI transition and pivotal Phase 3 Re-Spire (L606) studies.
Liquidia (NASDAQ: LQDA) will participate in two investor conferences in May 2026 with senior management presenting company updates.
Executives Michael Kaseta and Jason Adair will hold fireside chats and one-on-one meetings at BofA Securities Health Care Conference (May 13, 8:40 am PT, Las Vegas) and H.C. Wainwright Bioconnect at NASDAQ (May 19, 9:30 am ET, New York). Webcast access and replays are on the Investors page for at least 30 days.
Liquidia (Nasdaq: LQDA) will report first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
The webcast will stream and be archived for one year at the company investor events page.
Liquidia (NASDAQ: LQDA) will participate in investor conferences on April 14–15, 2026, offering one-on-one meetings and a webcasted fireside chat.
Executives attending include CEO Dr. Roger Jeffs, COO/CFO Michael Kaseta, and Chief Business Officer Jason Adair. Webcast replay and transcript will be archived on the company Investors page for at least 30 days.
Liquidia (NASDAQ: LQDA) reported full year 2025 results with YUTREPIA product sales of $148.3 million and $90.1 million in Q4. The company recorded >3,600 unique prescriptions and 2,900 patients treated since the June 2025 launch.
Liquidia ended 2025 with $190.7 million cash, reported Q4 net income of $14.6 million and Q4 adjusted EBITDA of $27.3 million, but a full‑year net loss of $68.9 million. Management plans sales‑force growth, more clinical studies for YUTREPIA, and pivotal trials for L606 funded from operations.
Liquidia (Nasdaq: LQDA) will report full year 2025 financial results on March 5, 2026. A live webcast is scheduled for 8:30 a.m. Eastern Time to discuss results and provide a corporate update. A rebroadcast will be archived on the company website for one year.
Liquidia (NASDAQ: LQDA) will present three clinical posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress in Dublin, Ireland, Jan 28–Feb 1, 2026.
The presentations cover interim and open-label clinical data for inhaled treprostinil products: LIQ861 (YUTREPIA) in PH-ILD from the ASCENT study to Week 24, and 48-week open-label data for investigational L606 in PAH and PH-ILD. Specific sessions: Paper 83 on Jan 29 (3:45–5:00 p.m. GMT), Paper 166 on Jan 30 (3:10–4:15 p.m. GMT), and Paper 82 on Jan 31 (9:55–11:00 a.m. GMT). Posters will be posted on Liquidia’s publications webpage after the conference.
Liquidia (NASDAQ: LQDA) reported preliminary, unaudited YUTREPIA net product sales of approximately $90.1M in Q4 2025 and $148.3M for full-year 2025, with >2,800 unique prescriptions since launch (May 23, 2025) and >2,200 patients started through December 2025. The company generated >$30M of positive cash flow in Q4 2025 and held approximately $190.7M cash and equivalents as of December 31, 2025. Commercial metrics include an 85% prescription-to-start conversion (through Nov 2025) and ~750 prescribers. Liquidia plans additional clinical studies and will present at the J.P. Morgan Healthcare Conference on Jan 14, 2026.
Liquidia (NASDAQ: LQDA) announced that CEO Dr. Roger Jeffs will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at approximately 5:15 p.m. PT / 8:15 p.m. ET at the Westin St. Francis in San Francisco.
A live, audio-only webcast will be available on the company Investors page and will be archived on the website for at least 30 days.
Liquidia Corporation (NASDAQ: LQDA) said company executives will present business updates at two investor conferences in November 2025. Fireside chats are scheduled at the UBS Global Healthcare Conference on Nov 10, 2025 at 4:15 p.m. ET in Palm Beach Gardens, Florida, and at the Jefferies London Healthcare Conference on Nov 18, 2025 at 9:00 a.m. ET / 1:00 p.m. GMT. Investors can access live webcasts and archived recordings via Liquidia’s investor events page. Archived recordings will remain available for at least 30 days after each event.